Internal Medicine Department/Service of Pneumology, Pourtalès Hospital, Neuchâtel, Switzerland
*Correspondence to Jean-Marc.Fellrath@h-ne.ch
Disclosure: Prof Jean-Marc Fellrath has received honoraria as a consultant and speaker from PneumRx Ltd and Pulmonx.
Support: The authors would like to thank Dr. Caroline Charles for medical writing assistance with this manuscript.
Received: 05.05.16 Accepted: 14.11.16
Citation: EMJ. 2016;1:44-51.
Endoscopic lung volume reduction (ELVR) mainly comprises endobronchial valves (EBV) and endobronchial coil (EBC) implants. EBV aims to occlude the most diseased and/or hyperinflated lobe thus inducing complete atelectasis. EBC therapy was developed a few years ago and is applicable independently of collateral flow and in patients presenting with disease dispersed throughout the upper and lower lobes. Bronchoscopic lung volume reduction with EBC is feasible in a wider range of patients (irrespective of collateral flow or disease homo/heterogeneity) than for EBV, and provides clinical benefits in the short-term, associated to an acceptable safety profile. The growing clinical and commercial experience of ELVR with nitinol coils will be reviewed in this article.
This article has a correction, made on 05.01.17.
The details of the correction are as follows: Unecessary references have been removed from the text.
The prior version of the paper is available on request, please contact email@example.com